Glucosio Baxter S.P.A.

Glucosio Baxter S.P.A. is an intravenous solution for injection that contains glucose monohydrate as its active ingredient. Although the exact concentration is not specified, the product is supplied as an aqueous solution intended for parenteral administration. It is classified as a carbohydrate solution (IV) and is marketed in the European Union under a prescription‑only status. The formulation provides a source of glucose for patients requiring fluid, electrolyte, or nutritional support.

Glucosio Baxter S.P.A. is used in clinical settings where rapid glucose supplementation, fluid balance, or parenteral nutrition is required.

- Treatment of hypoglycemia when oral glucose is not feasible. - Component of parenteral nutrition regimens for patients unable to receive enteral feeding. - Fluid and electrolyte replacement in perioperative or trauma care. - Support during prolonged fasting or critical illness to maintain blood glucose levels. - Adjunct in diagnostic procedures that require controlled glucose infusion. - Used to prevent ketosis in patients receiving high‑dose insulin therapy.

Glucosio Baxter S.P.A. may be associated with a range of adverse effects, most of which are related to the rapid increase in plasma glucose and the volume of fluid administered intravenously. The frequency and severity of these events depend on the infusion rate, total dose, and the patient’s underlying health status.

Common: - Transient hyperglycemia, often self‑limited. - Local irritation or phlebitis at the infusion site. - Mild electrolyte disturbances, such as slight sodium or potassium shifts. - Nausea, vomiting, or abdominal discomfort. - Headache or dizziness during rapid infusion.

Serious: - Severe hyperglycemia with osmotic diuresis and dehydration. - Acute hypersensitivity reactions, including urticaria, bronchospasm, or anaphylaxis. - Fluid overload leading to pulmonary edema or congestive heart failure exacerbation. - Hyperosmolar hyperglycemic state in susceptible patients.

When prescribing Glucosio Baxter S.P.A., clinicians should evaluate patient-specific factors and monitor for potential complications associated with intravenous glucose administration.

- Assess baseline blood glucose and adjust infusion rate to avoid hyperglycemia. - Evaluate fluid status; avoid use in patients with severe edema or heart failure. - Review electrolyte levels, particularly sodium, potassium, and magnesium, before and during therapy. - Use caution in individuals with renal impairment or uncontrolled diabetes mellitus. - Monitor for signs of infection at the catheter site and maintain aseptic technique. - Consider contraindications such as known hypersensitivity to glucose solutions.

Glucosio Baxter S.P.A. can interact with other intravenous therapies or medications that affect glucose metabolism, fluid balance, or electrolyte status.

Avoid: - Co‑administration with high‑dose insulin infusions without appropriate glucose monitoring. - Simultaneous infusion of other hypertonic carbohydrate solutions, which may cause excessive osmolar load. - Avoid mixing with calcium‑containing solutions, which can precipitate and cause line occlusion.

Use with caution: - Concurrent use of diuretics, which may exacerbate electrolyte shifts. - Administration alongside potassium‑sparing agents, requiring close electrolyte surveillance. - Use with vasopressors in patients with compromised cardiac function, monitoring for fluid overload. - Overlap with radiographic contrast agents, as both may affect renal perfusion. - Use cautiously with corticosteroids, as they may increase blood glucose levels.